Vivtex vs 10x Genomics

Side-by-side comparison of AI visibility scores, market position, and capabilities

10x Genomics leads in AI visibility (74 vs 52)
Vivtex logo

Vivtex

ChallengerBioTech

Oral Biologics Drug Delivery

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

AI VisibilityBeta
Overall Score
C52
Category Rank
#67 of 198
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
51
Gemini
50

About

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

Full profile
10x Genomics logo

10x Genomics

LeaderLife Sciences & BioTech

Genomics & Single-Cell Analysis

Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#7 of 198
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
80
Gemini
76

About

10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.

Full profile

AI Visibility Head-to-Head

52
Overall Score
74
#67
Category Rank
#7
84
AI Consensus
73
stable
Trend
stable
52
ChatGPT
71
51
Perplexity
80
50
Gemini
76
54
Claude
71
47
Grok
69

Key Details

Category
Oral Biologics Drug Delivery
Genomics & Single-Cell Analysis
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Vivtex
Oral Biologics Drug Delivery
Only 10x Genomics
Genomics & Single-Cell Analysis

Integrations

Only Vivtex

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.